|

Alisertib Clinical Trials

3 actively recruiting trials across 2 locations

No change since August 2026

Also known as: MLN8237, PB-8237

Pipeline

Phase 2: 3

Top Sponsors

  • Puma Biotechnology, Inc.3

Indications

  • Cancer3
  • Lung Cancer2
  • Recurrent Breast Cancer1
  • Small Cell Lung Cancer (SCLC)1
  • Metastatic Breast Cancer1

Other1 trial

A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)
Phase 2

Birmingham, Alabama1 trial

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

Alabama Oncology

Phase 2

Daphne, Alabama1 trial

A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer

Southern Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.